header-test
Utility Nav

For U.S. Healthcare Professionals only.

For U.S. Healthcare Professionals only.

Next Page Icon

Indication

Introducing COBENFY

The first new class* of schizophrenia treatment in over 3 decades1-4

Hero image

Three reasons to believe in COBENFY—the first and only M1/M4 muscarinic agonist1,3,5*

Alt text

FIRST IN CLASS* & HIGHLY SELECTIVE1,3,5†

Alt text

DEPTH & BREADTH OF EFFICACY‡§

Alt text

SAFETY & TOLERABILITY PROFILE

The mechanism of action of COBENFY in the treatment of schizophrenia is unclear1

* COBENFY is a combination of xanomeline (M1/M4 muscarinic agonist) and trospium chloride (muscarinic antagonist).1
Xanomeline binds to muscarinic receptors M1 to M5 with comparable affinity and exhibits higher agonist activity at the M1 and M4 receptors.1
Two randomized, double-blind, placebo-controlled, phase 3 studies assessed the safety and efficacy (change in PANSS total score from baseline at Week 5) of COBENFY—EMERGENT-2 (N=252) and EMERGENT-3 (N=256).3,6-8 See additional study design details.
§ EMERGENT-2 and EMERGENT-3 trial results evaluating change in PANSS total score from baseline at 5 weeks vs placebo (EMERGENT-2: -21.2 vs -11.6, P<0.0001; EMERGENT-3: -20.6 vs -12.2, P<0.001). Change from baseline at Week 5 in PANSS positive subscale score was also assessed as a secondary end point and achieved statistical significance vs placebo (EMERGENT-2: -6.8 vs -3.9, P<0.0001, EMERGENT-3: -7.1 vs -3.6,
P<0.001).3,6
  PANSS=Positive and Negative Syndrome Scale.
Cobenfy pill bottles

Capsules not shown at actual size.

Get your patients started on COBENFY today

References: 

  1. COBENFY. Prescribing Information. Bristol Myers Squibb Company; 2024.
  2. Paul SM, Yohn SE, Popiolek M, Miller AC, Felder CC. Muscarinic acetylcholine receptor agonists as novel treatments for schizophrenia. Am J Psychiatry. 2022;179(9):611-627.
  3. Kaul I, Sawchak S, Walling DP, et al. Efficacy and safety of xanomeline-trospium chloride in schizophrenia: a randomized clinical trial. JAMA Psychiatry. 2024;81(8):749-756.
  4. Nucifora FC Jr, Mihaljevic M, Lee BJ, Sawa A. Clozapine as a model for antipsychotic development. Neurotherapeutics. 2017;14(3):750-761.
  5. Dean B, Bakker G, Ueda HR, Tobin AB, Brown A, Kanaan RAA. A growing understanding of the role of muscarinic receptors in the molecular pathology and treatment of schizophrenia. Front Cell Neurosci. 2023;17:1124333.
  6. Kaul I, Sawchak S, Correll CU, et al. Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial. Lancet. 2024;403(10422):160-170.
  7. Data on file. Karuna Therapeutics, Inc., a Bristol Myers Squibb company; Boston, MA.
  8. Kaul I, Citrome L, Sawchak S, et al. Efficacy of KarXT (xanomeline–trospium) in schizophrenia: pooled results from the randomized, double-blind, placebo-controlled EMERGENT trials. Poster presented at: Neuroscience Education Institute Congress; November 9-12, 2023; Colorado Springs, CO.


Cobenfy, Cobenfy Cares, and the Cobenfy logo are trademarks of Karuna Therapeutics, Inc., a Bristol Myers Squibb company.
© 2024 Bristol-Myers Squibb Company. 1629-US-2400140 10/24